Please select the eligibility criteria that correspond to the clinical trial below.
Title: Effects of Decrease in Cholesterol Levels Induced by a Statin on Sperm Quality
Brief Summary: Recently, concerns about the effect of atorvastatin intake on men fertility have been raised. However, this statin has never been investigated regarding its influence on male fertility, notably sperm quality.

The aim of this pilot study is to evaluate the efficacy and the safety of a decrease of cholesterol blood levels, induced by taking atorvastatin, on sperm quality of normocholesterolaemic and healthy men without confounding factors.


Options:
A: Inclusion Criteria:

* Men :
* between 18 and 65 years ;
* with normal conventional semen parameters and negative semen culture according to WHO standards 1999 : volume ejaculate ≥ 2 ml, sperm count ≥ 20millions/ml, total motility ≥ 50% progressive motility ≥ 30%, typical forms ≥ 20%;
* with normal blood lipid profile: total cholesterol \< 2.50g/L, triglycerides \< 1.70g/L, HDL-C \> 0.35 g/L and LDL-C \< 2.2 g/L;
* without known pathology or ongoing treatment

Exclusion Criteria:

* Subjects with medical or surgical history that may make them at risk during the study,
* Subjects with cons-indications to taking atorvastatin
* Subjects with an active liver disease or increased level of serum transaminases
* Subjects with a history of allergy
* Subjects whose lipid parameters do not match the inclusions criteria or receiving lipid-lowering therapy
* Subject with abnormal semen analysis or cryptorchidism or a varicocele
* Subjects who participated in another clinical trial or other experimentation or other tolerance study of a drug
B: Inclusion Criteria:

* hypercholesterolemia

Exclusion Criteria:

* chronic renal disease
C: Inclusion Criteria:

* Diabetes mellitus treated with insulin or orl agents
* At least 50 years old

Exclusion Criteria:

* Previous cardiovascular events
* current or past (within last 30 days) treatment with aspirin
* current or past (within last 180 days) treatment with statins
D: Inclusion Criteria:

* Insulin treated patients with a newly diagnosed type 1 diabetes mellitus as defined by the ADA criteria at least two weeks but not later than 3 months after start of insulin treatment
* Age 18 to 39 years, inclusive
* Male patient or female patient using adequate contraceptive methods
* Tested positive for at least one of the three islet autoantibodies GAD65, IA2 or ICA

Exclusion Criteria:

* History of a malignancy
* Presence of a clinically significant hepatic or renal disease, as indicated, but not limited to a serum creatinine elevated more than ten percent above the upper limit of normal, elevation of AST or ALT more than 3 times the upper limit of normal
* Any other acute or chronic condition that may affect the patient's response to treatment or might be associated with an increased risk for the patient to participate, as judged by the investigator
* Current use of anti-inflammatory or immunomodulatory drugs, antihypertensive, lipid-lowering, or antidiabetic drugs other than insulin
* Pregnant or nursing women or women intending to become pregnant
* Known or suspected allergy to atorvastatin or any component of thr trial product
* Known myopathy, myalgia or myositis with a serum-CPK above 3 times the upper limit of normal
* Patients who had a severe blood loss (\>= 400 mL, e.g. blood donation) within 2 months prior to visit 2
* Any significant laboratory abnormality
* A serum LDL-cholesterol above 150 mg/dL at time of screening
* Unwillingness to comply with study procedures

Answer: A